French government delists certain Ipsen products

29 January 2012

French drugmaker Ipsen (Euronext: IPN) announced the French government’s decision to no longer reimburse its Gingko biloba products Tanakan, Tramisal and Ginkogink, presently manufactured at the industrial site of Dreux, France. This decision is linked to the French policy to reassess the reimbursement of a certain number of drugs by the French Social Security, the company said.

Although Tanakan, Tramisal and Ginkogink will be delisted from March 1, 2012, onwards, they will continue to be prescribed and delivered by health care professionals to patients in France. The company said the decision to delist these drugs underlines the relevance of Ipsen’s strategy to find a partner for its commercial operations in primary care with an OTX and OTC experience, as well as an acquirer for its industrial site at Dreux.

EGb 761, which is the active substance of Tanakan, is indicated and registered in many countries notably for the treatment of cognitive disorders in
the elderly as well as neurosensory disorders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK